The management of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been debated and is primarily centered on the choice between surgical myectomy and alcohol septal ablation. Decision making in these patients requires consideration of procedural risk, expertise and efficacy, and the long-term impact on patients' survival.
These debates have fallen largely along 2 lines. On 1 side, surgical myectomy is put forth as the most effective and safe therapy for relief of LVOT obstruction, and alcohol ablation is described as less efficacious and associated with an increased risk of pacemaker dependency, as well as a scar that is potentially proarrhythmic in a vulnerable patient. On the other side of the argument, alcohol ablation is presented as less invasive and thus patient preferred; the favorable outcomes of surgical myectomy are noted to be mainly from experienced centers, and the low number of these centers limits accessibility for those patients who may be myectomy candidates. So, how do we reconcile these differences in opinion when counseling our patients? And what do we need to resolve this debate?
GOALS OF THERAPY
Relief of morbidity and improvement in survival comprise the mantra of modern medical practice, and these therapeutic goals remain at the center of any discussion of the management of our patients with HCM. Certainly, for some patients, the predominant focus is on symptom relief, but this alleviation still must be pursued and achieved while minimizing harm and impairment of longevity.
For any given patient, the risk of the procedural options is a major driver of the therapy chosen because the clinical factors that lead to the risk profile From the Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota. Dr. Sorajja has reported that he has no relationships relevant to the contents of this paper to disclose. 
BASIS FOR CLINICAL PRACTICE
The benefits and the potential risks of surgery and alcohol septal ablation are the basis for the current practice recommendations, as put forth in multiple societal guidelines (2,3) (Central Illustration).
It is well accepted that surgery, when performed in experienced centers, is associated with a success rate of >90% for relief of LVOT obstruction and has a low operative mortality rate. Studies of surgical myectomy, which may include concomitant mitral valve repair, also have demonstrated long-term survival to be highly favorable and even comparable to normal longevity (4) (5) (6) (7) (8) . Notably, it is also recognized that outcomes of surgical myectomy performed outside of experienced centers are poor because of the technical expertise required for mastery of the procedure. In an analysis of 6,386 patients who had surgical myectomy at 1,049 U.S. hospitals between 2003 and 2011, the surgical mortality rate was 15.6% for patients in those centers in the lowest tertile of procedural volume, compared with 9.6% for the second tertile and 3.8% for the highest tertile (9) . Surgical centers with the highest level of expertise have exceptional outcomes, with operative mortality rates <1%, as described in a report on the collective experience of w3,700 patients at these institutions (10). Taken together, these data led to the guideline recommendation that the preferred treatment modality for drug-refractory symptoms of obstructive HCM is surgical myectomy performed in an experienced center.
Alcohol septal ablation emerged more than 20 years ago as an alternative to surgical myectomy for the treatment of symptomatic obstructive HCM (11).
Alcohol septal ablation has advantages that characteristically accompany catheter-based procedures, such as being relatively less invasive, potentially more widely available, and associated with a short hospital stay. The procedural mortality rate for alcohol septal ablation is reported to be 1% to 2% and is less dependent on operator experience than is surgical myectomy (9) 
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